What the 2020 FDA Boxed Warning Says About Benzodiazepine Dependence

Key Takeaways

• Since September 23, 2020, every benzodiazepine label in the United States carries a boxed warning about physical dependence and withdrawal reactions.
• The label says physical dependence can develop within days to weeks, even when the drug is taken exactly as prescribed.
• Physical dependence is not addiction, and the label treats the two separately.
• Stopping abruptly or cutting the dose fast can cause withdrawal reactions, including seizures, that can be life-threatening.
• The label recognizes protracted withdrawal, with symptoms lasting weeks to more than 12 months.
• If withdrawal reactions appear during a taper, the label tells prescribers to consider pausing or going back up a step, then reducing more slowly.
• The label sets no single tapering schedule, and the Ashton Manual and the Maudsley Deprescribing Guidelines fill in how slow is slow enough.

What did the FDA change on September 23, 2020?

On September 23, 2020, the United States Food and Drug Administration (FDA) required an updated boxed warning on the label of every benzodiazepine sold in the country. That means Xanax (alprazolam), Klonopin (clonazepam), Ativan (lorazepam), Valium (diazepam), and every other drug in the class. One warning, the same substance, on all of them.

A boxed warning is exactly what it sounds like. It is a box printed at the top of the prescribing information, and the FDA reserves it for the risks it considers most serious. Before September 2020, no benzodiazepine boxed warning said anything about physical dependence or withdrawal.

The update added five things to the box: abuse, misuse, addiction, physical dependence, and withdrawal reactions. The first three are the ones people tend to hear about. Yet, for a person who has taken a benzodiazepine as prescribed for years, the last two are the ones that matter. So, what does the box actually say about them?

Physical dependence can develop within days to weeks, even as prescribed.

The FDA’s own announcement put it plainly: physical dependence can occur when benzodiazepines are taken steadily for several days to weeks, even as prescribed. The label language is more formal. Continued use may lead to “clinically significant physical dependence,” and the risks of dependence and withdrawal increase with longer treatment duration and higher daily dose.

Read that again if you have been on a benzodiazepine for a long time. The label is not describing someone who took too many pills. It is describing a person who followed the directions on the bottle.

Why does dependence come on so quickly? Benzodiazepines boost the effect of gamma-aminobutyric acid (GABA), the brain’s main calming signal. When the boost is there every day, the brain likely adapts by turning down its own GABA receptors, and it then needs the drug just to feel normal.

The box names abuse, misuse, and addiction in one paragraph and physical dependence and withdrawal in another, and the label’s Drug Abuse and Dependence section defines each term on its own. That separation matters. Dependence is not addiction. A person who has taken Ativan exactly as prescribed for ten years and cannot stop has physical dependence, not addiction.

The label now says what patients had been telling their doctors for years.

Stopping abruptly can cause withdrawal reactions that are life-threatening.

The second half of the box is a warning about stopping. Abrupt discontinuation or rapid dosage reduction after continued use, it says, may precipitate acute withdrawal reactions, which can be life-threatening. The FDA’s announcement names seizures.

The label’s list of withdrawal reactions is long, and it will look familiar to anyone who has tried to quit. Anxiety, insomnia, panic attacks, tremor, muscle pain and stiffness, depersonalization, sound and light sensitivity, and memory impairment are all on it. The severe end of the list includes seizures, hallucinations, psychosis, and suicidal thinking.

While that list is frightening, it is also useful. A doctor who tells you that a withdrawal symptom is “just your anxiety coming back” is now disagreeing with the label of the drug they prescribed. The label is on your side.

The label calls severe withdrawal reactions life-threatening, which makes them a medical emergency. Seek help right away in these situations:

• Call 911 or go to the nearest emergency room for a seizure, severe confusion, hallucinations, or a fall with injury after a missed, reduced, or stopped dose.
• Call or text 988, the Suicide and Crisis Lifeline, for thoughts of suicide or self-harm at any point during a taper.
• Tell your prescriber the same day about any dose change that set off symptoms, so the plan can be adjusted.

The label recognizes protracted withdrawal.

Is benzodiazepine withdrawal permanent? For most people it is not, but after months of symptoms that come and go, it can feel that way. The updated label speaks to this directly. In its Warnings and Precautions section it describes a protracted withdrawal syndrome, with withdrawal symptoms lasting weeks to more than 12 months.

That one sentence did a lot of work for a lot of patients. For years, a person still sick a year after their last dose was told that benzodiazepines leave the body in days, so the problem must be something else. Now the label itself says otherwise, and it is public on DailyMed, the federal drug label database, in Sections 5 and 9.

Patients often describe printing those two sections and bringing them to an appointment. Some describe watching a doctor read the label of a drug they have prescribed for years, for the first time, in silence. Nothing about that scene is the patient’s fault.

The label says to taper gradually, and it says what to do when symptoms appear.

The box ends with an instruction: to reduce the risk of withdrawal reactions, use a gradual taper to discontinue the drug or reduce the dosage. The dosing section of each updated label goes one step further. If a patient develops withdrawal reactions during a taper, the label says to consider pausing the taper or increasing the dosage to the previous tapered dosage level, and then to decrease the dosage more slowly.

Pause on that for a moment. Holding a dose, or going back up a step, is written into the prescribing information as an option to consider when symptoms appear. A hold is not a failure. It is the label working as intended.

Unfortunately, the label does not say how slow is slow enough. Some labels set a ceiling on how fast the dose may fall, but the FDA’s announcement states that there are no standard benzodiazepine tapering schedules suitable for all patients, and it directs prescribers to create a patient-specific plan. It then leaves the rest to you and your doctor.

How slow is slow enough?

This is where the two other references worth knowing come in. The Ashton Manual, written by the late Professor C. Heather Ashton, explains in Chapter II why anyone withdrawing from long-term benzodiazepines must reduce the dosage slowly, and why switching to diazepam helps many people on potent, short-acting benzodiazepines. Diazepam leaves the body slowly and comes in small tablet and liquid strengths, so each step down can be small and the blood level falls smoothly between doses.

That approach, known on this site as the Ashton Manual method, has a companion. The Maudsley Deprescribing Guidelines add the shape of the curve. Because the effect at the receptor does not fall in a straight line with the dose, the guidelines recommend hyperbolic tapering, meaning that each reduction gets smaller as the dose gets lower.

Think of a dimmer switch rather than a wall switch. Stopping cold turkey flips the room dark in an instant, and the label calls that dangerous. Turning the dimmer slowly lets your eyes adjust, and, as anyone with a dimmer knows, most of the change happens in the last part of the knob’s travel.

Turn the knob slowly, and slowest near the bottom. How long that takes is different for every patient, and there is a longer answer on this site to the question of how long a benzodiazepine taper takes.

What does the warning mean for you, on a long-term prescription?

First, it means you were owed a conversation that many patients never got. The updated labels direct prescribers to inform patients that continued use may lead to clinically significant physical dependence, that abrupt discontinuation or rapid dosage reduction may precipitate life-threatening withdrawal reactions, and that stopping may require a slow taper. Genuine informed consent goes further than the label: the risks first, then the alternatives, including no medication at all, then an exit plan, then your right to say no. If you did not get that conversation, the failure was not yours.

Second, it is reasonable to ask harder questions than you once did. Many patients were started on a benzodiazepine with no mention of dependence at all, and the label now spells the risk out. That same label is the best tool you have for the next conversation, because it is hard to argue with the paper that came in the box.

Third, the pace is yours to negotiate. If a reduction sets off symptoms, your doctor should be willing to slow down or hold, and the label backs you on that. If a step goes well, you and your doctor may agree to take the next one a bit sooner, as tolerated. That is what medically supervised benzodiazepine tapering means in practice.

The nervous system that adapted to the drug can adapt back. It does so on its own schedule, not the calendar’s, and it does so best when nothing is rushed. Given time and a slow enough dimmer, it usually heals.

What else do patients ask about the 2020 warning?

Does the boxed warning mean you should stop taking your benzodiazepine?

No. The warning says the opposite about stopping: never abruptly, and never fast. It is a reason to ask your doctor about an exit plan on a timeline you can tolerate, not a reason to throw the bottle away.

Does the 2020 warning cover Ambien and the other z-drugs?

The 2020 class-wide box applies to benzodiazepines only. Z-drugs such as Ambien (zolpidem) and Lunesta (eszopiclone) were not part of that action, although they act on the same GABA receptors and can also produce physical dependence. In practice, they are tapered on the same principles.

Where can you read the updated label yourself?

Search DailyMed for your medication by name and open the current prescribing information. The boxed warning sits at the top, Section 5 covers dependence and withdrawal reactions, and Section 9 covers drug abuse and dependence. Printing those pages before an appointment is not a bad idea.

How does Dr. Leeds’ practice apply the warning?

Dr. Leeds is an osteopathic physician and deprescribing specialist in Fort Lauderdale, Florida, and his practice treats benzodiazepine dependence the way the label now directs: as a medical condition that ends with a gradual taper on a patient-specific plan. He works directly with every patient by telemedicine throughout Florida, with a crossover taper to diazepam where it helps and hyperbolic reductions per the Maudsley Deprescribing Guidelines, often using liquid formulations so that the last steps can be very small. When a reduction sets off symptoms, the plan is adjusted with the patient, which may mean a short pause or a smaller next step, as the label suggests, and the pace is set with the patient rather than for the patient. Contact the office today to ask whether a slow, supervised taper is the right next step.

This article is educational. It is not medical advice, and reading it does not create a doctor-patient relationship. Decisions about starting, continuing, or tapering any medication should be made with your own physician.